IGF-1 DES vs Plecanatide
Head-to-head comparison of IGF-1 DES (Des(1-3) Insulin-like Growth Factor 1) and Plecanatide (Plecanatide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | IGF-1 DES | Plecanatide |
|---|---|---|
| Category | Growth Hormone | Gastrointestinal |
| Full Name | Des(1-3) Insulin-like Growth Factor 1 | Plecanatide |
| Molecular Weight | 7365 Da | Approx. 1620 Da |
| Half-Life | ~20-30 minutes | Local intestinal action; systemic half-life not clinically meaningful |
| Amino Acids | 67 | 16 |
| Typical Dose | — | 3 mg once daily |
| Route | — | Oral |
| Purity | >98% | ≥98% |
| Studies Count | 65 | 350 |
| Research Status | Active Research | Clinical |
IGF-1 DES Benefits
- ✓Highly potent localized muscle growth, enhanced protein synthesis, satellite cell proliferation, does not bind to IGFBPs, rapid onset
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
IGF-1 DES Dosing
50-150 mcg per injection site bilaterally post-workout. 4-6 week cycles due to potency. Multiple daily injections in research.
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
IGF-1 DES Side Effects
- ⚠Hypoglycemia (dose-dependent), localized swelling, shorter duration limits systemic exposure compared to IGF-1 LR3.
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Research Overview
IGF-1 DES
Missing first three amino acids (Gly-Pro-Glu) eliminates IGFBP binding, resulting in 100% bioavailable IGF-1R stimulation. Activates PI3K/Akt/mTOR for protein synthesis and satellite cell proliferation.
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.